Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma

Lv, Qiao‐Li; Du, Hong; Liu, Yanling; Huang, Yuang-Tao; Wang, Guihua; Zhang, Xue; Chen, Shuhui; Zhou, Hong‐Hao

doi:10.3892/or.2017.5762

Cited by 33 publications

(33 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Substantial evidence indicates that miRNAs play important roles in most biological processes in both normal development and in various diseases, including cancer (12,13). In recent years, miRNA dysregulation has been reported in various types of human cancers, such as GC (14), bladder cancer (15), colorectal cancer (16), glioma (17) and lung cancer (18). Furthermore, aberrantly expressed miRNAs are associated with tumourigenesis and tumour development and affect cell proliferation, cell cycle distribution, apoptosis, migration, invasion, angiogenesis and epithelial-mesenchymal transition (19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1

et al. 2017

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most commonly diagnosed malignant disease and the third leading cause of cancer‑related deaths worldwide. Recently, numerous microRNAs (miRNAs) have been determined to contribute to GC initiation and progression, suggesting that miRNAs may be developed as effective diagnostic and prognostic molecular biomarkers and can be investigated as therapeutic targets for patients with this disease. Therefore, further investigation of the miRNAs involved in GC development represents an opportunity to improve the prognosis of GC patients. miRNA‑454 (miR‑454) is abnormally expressed in multiple types of human cancer. However, the expression pattern, biological roles and underlying mechanism of miR‑454 in GC remain unclear and require further investigation. In the present study, we assessed miR‑454 expression in GC tissues and cell lines. We also explored the effects of miR‑454 on the biological behaviours of tumour cells and the underlying molecular mechanisms of miR‑454. The results revealed that miR‑454 was significantly downregulated in GC tissues and cell lines. Low miR‑454 expression was positively associated with lymph node metastasis, invasive depth and TNM stage. Additionally, upregulation of miR‑454 inhibited cell proliferation and invasion and induced the apoptosis of the GC cells. Subsequently, mitogen‑activated protein kinase 1 (MAPK1) was identified as a direct target of miR‑454. MAPK1 was upregulated in GC tissues and was found to be negatively correlated with the miR‑454 expression level. Downregulation of MAPK1 also suppressed GC cell proliferation and invasion and increased apoptosis, thereby resembling the suppressive effects of miR‑454 overexpression in GC. Moreover, upregulation of MAPK1 reversed the tumour‑suppressive effects of miR‑454 in GC. Collectively, our data demonstrated that miR‑454 may play tumour‑suppressing roles in GC through the regulation of MAPK1, suggesting that miR‑454 may be a novel biomarker and therapeutic target for patients with this disease.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1

et al. 2017

View full text Add to dashboard Cite

show abstract

“…miRNA-320b is down-regulated in various cancers, and it is associated with tumorigenesis and poor prognosis in glioma. 42 miRNA-375 was also shown to be often down-regulated in NSCLC, 43,44 breast cancer, 45 colorectal cancer, [46][47][48][49] oesophageal cancer, 50,51 gastric cancer, 52,53 and pancreatic cancer. 54,55 It is associated with tumour proliferation and metastases.…”

Section: Discussionmentioning

confidence: 99%

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

et al. 2018

View full text Add to dashboard Cite

Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this drug. We investigated herein immune-related blood markers in patients with advanced NSCLC treated with nivolumab. Plasma of 43 consecutive patients were prospectively collected at time of the diagnosis of cancer, at the initiation of nivolumab and at the first tumour evaluation (2 months). Concentrations of PD-L1 (sPD-L1), soluble PD-L2 (sPD-L2), Interleukine-2 (sIl-2), Interferon-gamma (sIFN-γ), and Granzyme B (sGranB) were quantified by ELISA. Cell free RNA was quantified by Reverse Transcriptase -PCR), and plasmatic microRNAs (miRNAs) were evaluated by targeted sequencing. Expression of PD-L1 on tumour biopsies was performed by immunohistochemistry using E13LN. High sPD-L1 at 2 months and increase of sPD-L1 concentrations were associated with poor response and absence of clinical benefit (nivolumab treatment less than 6 months). The variation of sPD-L1 concentrations were confirmed by RNA quantification. sPD-L1 concentrations were not correlated with PD-L1 expression on corresponding tumour samples. Low sGranB at nivolumab initiation was also associated with poor response. High sPD-L1 and low sGranB were associated with poor progression-free survival (PFS) and overall survival (OS). Low sPD-L2, low sIl-2 and high sIFN-γ were associated with grade 3-4 toxicities. Finally, miRNA screening showed that patients with clinical benefit (n = 9) had down-expression of miRNA-320b and -375 compared to patients with early progression at 2 months (n = 9). In conclusion, our results highlight the interest of circulating biomarkers in patients treated with nivolumab.

show abstract

“…microRNAs (miRs or miRNAs) are a class of endogenous non-coding small RNAs, 18-24 nucleotides in length, that are ubiquitous in viruses and eukaryote cells in highly conserved sequences. It has been estimated that up to 50% of human protein-coding genes are regulated by miRNAs (4). Each miRNA has the potential to regulate hundreds of RNAs, and their expression is associated with tissue status and disease subtype (5).…”

Section: Introductionmentioning

confidence: 99%

“…miRNAs have been demonstrated to serve an important role in the development and prognosis of glioma. Lv et al (4) reported that low miR-320b expression in glioma was associated with poor patient prognosis. The upregulation of miR-320b enhanced apoptosis and attenuated the proliferation, migration and invasive abilities of glioma cells.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1

et al. 2019

View full text Add to dashboard Cite

microRNA (miR)-6852 has been demonstrated to suppress the progression of gastric, colorectal and cervical cancer. The mechanism by which miR-6852 regulates glioma cells is yet to be elucidated. In the present study, reverse transcription-quantitative PCR analysis was used and the results demonstrated that miR-6852 expression was reduced in glioma tissues and cells. Cell counting kit-8 and transwell assay analysis indicated that proliferation, migration and invasion of A172 cells in the miR-6852 mimic group were lower than in the miR-NC group. Compared with the Inh-NC group, A172 cells of the Inh-miR-6852 group exhibited higher proliferation, migration and invasion. Additionally, the results indicated that lymphoid enhancer binding factor 1 (LEF1) was directly inhibited by miR-6852 and LEF1 expression was negatively correlated with miR-6852 expression in glioma tissues. Furthermore, the restoration of LEF1 reversed the effects of the miR-6852 mimics. The present findings suggested that miR-6852 inhibited glioma cells proliferation, migration and invasion by targeting the suppression of LEF1. Recently, miR-6852 has been demonstrated to be associated with the development of tumors, including those in gastric, colorectal and cervical cancer (9-11). The association of miR-6852 with glioma remains undetermined. Therefore, the present study aimed to assess miR-6852 expression in glioma, and further determine the effect of miR-6852 in the regulation of glioma progression. Materials and methodsGlioma tissue collection. A total of 32 pairs of glioma tissues (14 males and 18 females; age range, 31-56 years old; median age, 47 years old) and corresponding normal tissues were collected during biopsy from Affiliated Hospital of Hebei University (Hebei, China) between October 2014 and October 2016 for the current study. Normal tissues were derived from the temporal lobes and saddle area 2 cm away from tumor tissues. All glioma tissues were obtained from patients upon first diagnosis of glioma. Among these patients, 18 cases were high-grade and 14 cases were low-grade. All patients did not recieve radiotherapy or chemotherapy prior to surgery. Patients

show abstract

Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma

Cited by 33 publications

References 31 publications

MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1

MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

MicroRNA‑6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1

Contact Info

Product

Resources

About